Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Cited by (1,002)

Items 101–200 of 1,002

1. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
   Antonio Pierangelo Palumbo, Patrizia Falco, Paolo Corradini, Antonietta Pia Falcone, Francesco Di Raimondo, Nicola Giuliani, Claudia Crippa, Giovannino Ciccone, Paola Omedè, Maria Teresa Ambrosini et al. · 2007 · Journal of Clinical Oncology
2. POEMS syndrome
   Angela A. Dispenzieri · 2007 · Blood Reviews
3. Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
   Stephen Schey, Paul A. Fields, J. Blake Bartlett, Ian Clarke, G. Ashan, Robert Knight, Matthew J. Streetly, Angus George Dalgleish · 2004 · Journal of Clinical Oncology
4. Prognostic value of bone marrow angiogenesis in multiple myeloma.
   S. Vincent Rajkumar, Traci L. Leong, P C Roche, Rafaël Fonseca, Angela A. Dispenzieri, Martha Q. Lacy, John Anthony Lust, Thomas Elmer Witzig, Robert A. Kyle, Morie Abraham Gertz et al. · 2000 · PubMed
5. Thalidomide for treatment of multiple myeloma: 10 years later
   Antonio Pierangelo Palumbo, Thierry T.F. Facon, Pieter Sonneveld, Joan Bladé, Massimo Offidani, Francesca Gay, Philippe Moreau, Anders Waage, Andrew G Spencer, Heinz Ludwig et al. · 2008 · Blood
6. Guidelines on the diagnosis and management of multiple myeloma 2005
   Alastair G. Smith, Finn Wislöff, Diana Samson · 2005 · British Journal of Haematology
7. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
   Thierry T.F. Facon, Hervé Avet‐Loiseau, Gaëlle Guillerm, Philippe Moreau, Franck Geneviève, Marc Zandecki, Jean‐Luc Laï, Xavier P Leleu, Jean‐Pierre Jouet, F Bauters et al. · 2001 · Blood
8. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
   Paul Gerard Guy Richardson, Pieter Sonneveld, Michael W. Schuster, Edward Allen Stadtmauer, Thierry T.F. Facon, Jean‐Luc Harousseau, Dina Ben‐Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Ellen Reece et al. · 2009 · British Journal of Haematology
9. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
   Azra Raza, Peter Meyer, Diya Dutt, Francesca Zorat, Laurie Lisak, Fabiana Nascimben, Morne du Randt, Christopher Kaspar, Chase Goldberg, Jerome M. Loew et al. · 2001 · Blood
10. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
    Keith S. Dredge, J. Blake Marriott, Claire Macdonald, H‐W Man, R Chen, George W. Muller, David Stirling, Angus George Dalgleish · 2002 · British Journal of Cancer
11. Angiogenesis-dependent diseases
    Judah Folkman · 2001 · Seminars in Oncology
12. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
    Luciano J. Costa, Ilene K. Brill, James L. Omel, Kelly Nicole Godby, Shaji Kunnathu Kumar, Elizabeth E. Brown · 2017 · Blood Advances
13. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
    Zhu, Yuan Xiao, Kortuem, K. Martin, Stewart, A. Keith · 2013 · Leukemia & Lymphoma
14. Drug repurposing in oncology—patient and health systems opportunities
    Francesco Bertolini, Vikas P. Sukhatme, Gauthier Bouche · 2015 · Nature Reviews Clinical Oncology
15. Treatment of multiple myeloma
    Rajkumar, S. Vincent · 2011 · Nature Reviews Clinical Oncology
16. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    S. Vincent Rajkumar, Ruben A. Mesa, Rafaël Fonseca, Georgene S. Schroeder, Matthew F. Plevak, Angela A. Dispenzieri, Martha Q. Lacy, John Anthony Lust, Thomas Elmer Witzig, Morie Abraham Gertz et al. · 2002 · PubMed
17. Drug resistance in multiple myeloma
    Pawel J. Robak, Izabela Dróźdż, Janusz Szemraj, Tadeusz Robak · 2018 · Cancer Treatment Reviews
18. Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells
    Aldo Maria Roccaro, Teru Hideshima, Noopur S Raje, Shaji Kunnathu Kumar, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Doménico Ribatti, Beatrice Nico, Angelo Vacca et al. · 2006 · Cancer Research
19. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A. Mesa, David P. Steensma, Animesh Dev Pardanani, Chin‐Yang Li, Michelle Ann Elliott, Scott H. Kaufmann, Gregory A. Wiseman, Leigh A. Gray, Georgene S. Schroeder, Terra L. Reeder et al. · 2003 · Blood
20. Thalidomide and dexamethasone combination for refractory multiple myeloma
    Meletios Athanasios Dimopoulos, Konstantinos Zervas, G. Kouvatseas, Eleni P. Galani, Vassiliki Grigoraki, Christos Kiamouris, E. Vervessou, E. Samantas, C.A. Papadimitriou, Olga Economou et al. · 2001 · Annals of Oncology
21. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
    Vaishali Sanchorawala, Anthony C Shelton, Stephen B. Lo, Cindy Varga, John Mark Sloan, David C. Seldin · 2016 · Blood
22. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
    D. Chang, Nancy Liu, Virginia M. Klimek, Hani Hassoun, Amitabha Mazumder, Stephen D. Nimer, Sundar Jagannath, Madhav V. Dhodapkar · 2006 · Blood
23. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
    Peter M. Fayers, Antonio Palumbo, Cyrille Hulin, Anders Waage, Pierre Wijermans, Meral Beksaç, Sara Bringhen, Jean‐Yves Mary, Peter Gimsing, Fabian Termorshuizen et al. · 2011 · Blood
24. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
    Keith S. Dredge, Rebecca Horsfall, Simon P. Robinson, Linghua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George W. Muller, Peter H Schafer, David Stirling et al. · 2005 · Microvascular Research
25. Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
    Annie Pei-Fen Chiang, Atul Janardhan Butte · 2009 · Clinical Pharmacology & Therapeutics
26. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
    Vaishali Sanchorawala, Daniel G. Wright, Michael Alan Rosenzweig, Kyle T. Finn, Salli A Fennessey, Jerome B. Zeldis, Martha M. Skinner, David C. Seldin · 2006 · Blood
27. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
    Maurizio Zangari, Eric R. Siegel, Bart Barlogie, Elias J. Anaissie, Fariba Saghafifar, Athanasios Fassas, Christopher Morris, Louis M. Fink, Guido J. K. Tricot · 2002 · Blood
28. Solitary plasmacytoma treated with radiotherapy: Impact of tumor size on outcome
    Richard W. C. Tsang, Mary Krystyna Gospodarowicz, Melania Pintilie, Andrea Bezjak, Woodrow A. Wells, David C. Hodgson, A. Keith Stewart · 2001 · International Journal of Radiation Oncology*Biology*Physics
29. Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
    Pierre Wijermans, M. Ronald Schaafsma, Fabian Termorshuizen, Rianne Ammerlaan, Shulamiet H. Wittebol, Harm A. M. Sinnige, Sonja Zweegman, Marinus van Marwijk Kooy, René van der Griend, Henk M. Lokhorst et al. · 2010 · Journal of Clinical Oncology
30. Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
    Laubach, J, Garderet, L, Mahindra, A, Gahrton, G, Caers, J, Sezer, O, Voorhees, P, Leleu, X, Johnsen, H E, Streetly, M et al. · 2016 · Leukemia
31. Angiogenesis Research: Guidelines for Translation to Clinical Application
    Timothy D. Browder, Jan E.W. Palmblad, Judah Folkman · 2001 · Thrombosis and Haemostasis
32. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study
    Kristinsson, Sigurdur Y., Pfeiffer, Ruth M., Björkholm, Magnus, Goldin, Lynn R., Schulman, Sam, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Wahlin, Anders, Turesson, Ingemar, Landgren, Ola · 2010 · Blood
33. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
    Sarah A. Holstein, Philip L. McCarthy · 2017 · Drugs
34. The thalidomide saga
    Melchert, Magda, List, Alan · 2007 · The International Journal of Biochemistry & Cell Biology
35. Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences
    Kenneth Carl Anderson · 2005 · Seminars in Hematology
36. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
    Gunnar Juliusson, Fredrik Celsing, Ingemar Turesson, Stig Lenhoff, Magnus Adriansson, Claes Malm · 2000 · British Journal of Haematology
37. A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
    Axel G. Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie von Lilienfeld‐Toal, Katjana S. Orlopp, Ingo G.H. Schmidt‐Wolf, Marcus Gorschlüter · 2006 · British Journal of Haematology
38. Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
    Robert S. Kerbel, Joanne Yu, Jennifer Tran, Shan Man, Alicia Viloria‐Petit, Giannoula Lakka Klement, Brenda Lynn Coomber, Janusz W. Rak · 2001 · Cancer and Metastasis Reviews
39. Curing myeloma at last: defining criteria and providing the evidence
    Bart Barlogie, Alan Mitchell, Frits van Rhee, Joshua Epstein, Gareth John Morgan, John J. Crowley · 2014 · Blood
40. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
    Enrique M. Ocio, Paul Gerard Guy Richardson, S. Vincent Rajkumar, Antonio Pierangelo Palumbo, María‐Victoria Mateos, Robert Zygmunt Orlowski, Shaji Kunnathu Kumar, Saad Z. Usmani, David Roodman, Rubén Niesvizky et al. · 2013 · Leukemia
41. Drug repositioning: Progress and challenges in drug discovery for various diseases
    Hua, Yi, Dai, Xiaowen, Xu, Yuan, Xing, Guomeng, Liu, Haichun, Lu, Tao, Chen, Yadong, Zhang, Yanmin · 2022 · European Journal of Medicinal Chemistry
42. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
    A. Waage, P. Gimsing, P. Fayers, N. Abildgaard, L. Ahlberg, B. Björkstrand, K. Carlson, I. Dahl, Karin Forsberg, N. Gulbrandsen et al. · 2010 · Blood
43. NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
    Shaima’a Hamarsheh, Robert Zeiser · 2020 · Frontiers in Immunology
44. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
    Ruben A. Mesa, Curtis A. Hanson, S. Vincent Rajkumar, Georgene S. Schroeder, Ayalew Tefferi · 2000 · Blood
45. Thalidomide — A Revival Story
    Noopur S Raje, Kenneth Carl Anderson · 1999 · New England Journal of Medicine
46. Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma
    Keren Osman, Raymond L. Comenzo, S. Vincent Rajkumar · 2001 · New England Journal of Medicine
47. Multiple Myeloma
    Kenneth Carl Anderson, Melissa Alsina, William Bensinger, Janet Sybil Biermann, Asher Alban Chanan-Khan, Adam D. Cohen, Steven Michael Devine, Benjamin Djulbegović, Cristina Gasparetto, Carol Ann Huff et al. · 2009 · Journal of the National Comprehensive Cancer Network
48. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
    Giovanni O. Palladini, Vittorio Perfetti, Stefano Perlini, Laura Piera Obici, Francesca Lavatelli, Riccardo Caccialanza, Rosangela Invernizzi, Benedetto Comotti, Giampaolo Merlini · 2004 · Blood
49. Clinically relevant end points and new drug approvals for myeloma
    Kenneth Carl Anderson, Robert A. Kyle, S. Vincent Rajkumar, A. Keith Stewart, Diane M. Weber, Paul Gerard Guy Richardson · 2007 · Leukemia
50. Thalidomide as initial therapy for early-stage myeloma
    S. Vincent Rajkumar, Morie Abraham Gertz, Martha Q. Lacy, Angela A. Dispenzieri, Rafaël Fonseca, Susan Michelle Geyer, Nancy L. Iturria, Shaji Kunnathu Kumar, John Anthony Lust, Robert A. Kyle et al. · 2003 · Leukemia
51. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Jatin J. Shah, Edward Allen Stadtmauer, Rafat Abonour, Adam D. Cohen, William Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, Suzanne Lentzsch, Dan T. Vogl, Christina L. Gomes et al. · 2015 · Blood
52. Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
    Frank A. Scappaticci · 2002 · Journal of Clinical Oncology
53. Forty-Year Journey of Angiogenesis Translational Research
    Yihai Cao, Jack L. Arbiser, Robert J. D’Amato, Patrìcia A. D'Amore, Donald E. Ingber, Robert S. Kerbel, Michael Klagsbrun, Sharon Lim, Marsha A. Moses, Bruce R. Zetter et al. · 2011 · Science Translational Medicine
54. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
    Lacy, Martha Q., Allred, Jacob B., Gertz, Morie A., Hayman, Suzanne R., Short, Kristen Detweiler, Buadi, Francis, Dispenzieri, Angela, Kumar, Shaji, Greipp, Philip R., Lust, John A. et al. · 2011 · Blood
55. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
    Michel Delforge, Joan Bladé, Meletios Athanasios Dimopoulos, Thierry T.F. Facon, Martin H. Kropff, Heinz Ludwig, Antonio Pierangelo Palumbo, Philip Van Damme, Jesús F. San Miguel, Pieter Sonneveld · 2010 · The Lancet Oncology
56. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari, Bart Barlogie, Elias J. Anaissie, Fariba Saghafifar, Paul Eddlemon, Joth L. Jacobson, Choon‐Kee Lee, Raymond Thertulien, Giampaolo Talamo, Teri Thomas et al. · 2004 · British Journal of Haematology
57. Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases
    William H. Rastetter, Arturo Molina, Christine A. White · 2004 · Annual Review of Medicine
58. Angiogenic inhibitors: a new therapeutic strategy in oncology
    Giampietro Gasparini, Raffaele Longo, Masakazu Toi, Napoleone Ferrara · 2005 · Nature Clinical Practice Oncology
59. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions
    Constantine S. Mitsiades, Nicholas Mitsiades, Nikhil C. Munshi, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2006 · European Journal of Cancer
60. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
    S. Vincent Rajkumar · 2018 · American Journal of Hematology
61. Multiple Myeloma: Diagnosis and Treatment
    S. Vincent Rajkumar, Robert A. Kyle · 2005 · Mayo Clinic Proceedings
62. Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
    S. Vincent Rajkumar · 2014 · American Journal of Hematology
63. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
    Antonio Pierangelo Palumbo, Sara Bringhen, Alessandra Larocca, Davide Rossi, Francesco Di Raimondo, Valeria Magarotto, Francesca F. Patriarca, Anna Levi, Giulia Benevolo, Iolanda Donatella Vincelli et al. · 2014 · Journal of Clinical Oncology
64. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
    Heinz Ludwig, Roman Hájek, Elena Tóthová, Johannes W. Drach, Zdeněk Adam, Boris Labar, Miklós Egyed, Ivan Špıčka, Heinz Gisslinger, Richard Greil et al. · 2008 · Blood
65. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases
    Karl‐Josef Kallen · 2002 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
66. Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis
    Maureen R. Horton, Victoria Santopietro, Leena Mathew, Karen M. Horton, Albert J. Polito, Mark C. Liu, Sonye Karen Danoff, Noah Lechtzin · 2012 · Annals of Internal Medicine
67. Circulating endothelial progenitor cells in multiple myeloma: implications and significance
    Hanwei Zhang · 2004 · Blood
68. Thalidomide: A review of approved and investigational uses
    Samuel James Matthews, Christopher P. McCoy · 2003 · Clinical Therapeutics
69. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
    Sham Mailankody, Ruth M. Pfeiffer, Sigurdur Yngvi Kristinsson, Neha Korde, Magnus Björkholm, Lynn R. Goldin, Ingemar Turesson, Ola Landgren · 2011 · Blood
70. Novel therapies targeting the myeloma cell and its bone marrow microenvironment
    Teru Hideshima, Dharminder Chauhan, Klaus Podar, Robert L. Schlossman, Paul Richardson, Kenneth C. Anderson · 2001 · Seminars in Oncology
71. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
    Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J et al. · 2018 · Leukemia
72. Chasing molecular glue degraders: screening approaches
    Domostegui, Ana, Nieto-Barrado, Luis, Perez-Lopez, Carles, Mayor-Ruiz, Cristina · 2022 · Chemical Society Reviews
73. Bone marrow angiogenesis in multiple myeloma
    Angelo Vacca, Doménico Ribatti · 2005 · Leukemia
74. NF-κB in cancer therapy
    Feng Li, Jingwen Zhang, Frank Arfuso, Arunachalam Chinnathambi, Mohamed E. Zayed, Sulaiman Ali Alharbi, Alan Prem Kumar, Kwang Seok Ahn, Gautam Sethi · 2015 · Archives of Toxicology
75. Management of thalidomide toxicity.
    Irene M. Ghobrial, S. Vincent Rajkumar · 2003 · PubMed
76. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
    Waqas Rehman, Lisa M. Arfons, Hillard Michael Lazarus · 2011 · Therapeutic Advances in Hematology
77. Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
    Ingemar Turesson, Ramón Vélez, Sigurdur Yngvi Kristinsson, Ola Landgren · 2009 · Journal of Clinical Oncology
78. Thalidomide for Chronic Sarcoidosis
    Robert Phillip Baughman, Marc A. Judson, Alvin S. Teirstein, David R. Möller, Elyse E. Lower · 2002 · CHEST Journal
79. Venous Thromboembolism in the Hematologic Malignancies
    Anna Falanga, Marina Marchetti · 2009 · Journal of Clinical Oncology
80. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
    Nizar Jacques Bahlis, Jennifer M. Grad, Ileana Jordan-McMurry, Jim Neil, Isildinha Reis, Mohamed A. Kharfan‐Dabaja, James R. Eckman, Mark S. Goodman, Hugo Francisco Fernandez, Lawrence Boise et al. · 2002 · PubMed
81. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
    Efstathios Kastritis, Konstantinos Zervas, Argiris S. Symeonidis, Evangelos Terpos, S Delimbassi, Nikolaos I. Anagnostopoulos, Evridiki Michali, Athanasios Zomas, Eirini Katodritou, Dimitra Gika et al. · 2009 · Leukemia
82. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
    Noopur S Raje, Shaji Kunnathu Kumar, Teru Hideshima, Aldo Maria Roccaro, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Dharminder Chauhan, Nikhil C. Munshi, Simon R. Green et al. · 2005 · Blood
83. In silico drug repositioning – what we need to know
    Zhichao Liu, Hong Fang, Kelly Reagan, Xiaowei Xu, Donna L. Mendrick, William Slikker, Weida Tong · 2012 · Drug Discovery Today
84. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
    Marco Angelo Colleoni, Laura Orlando, G. Sanna, Andrea Rocca, Patrick Maisonneuve, G. Peruzzotti, Raffaella Ghisini, Maria Teresa Sandri, Laura Zorzino, F. Nolè et al. · 2005 · Annals of Oncology
85. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
    An, Jian, Ponthier, Charles M., Sack, Ragna, Seebacher, Jan, Stadler, Michael B., Donovan, Katherine A., Fischer, Eric S. · 2017 · Nature Communications
86. Properties of thalidomide and its analogues: Implications for anticancer therapy
    Steven K.O. Teo · 2005 · The AAPS Journal
87. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
    Patrycja M. Nowak-Sliwinska, Léonardo Scapozza, Ariel Ruiz i Altaba · 2019 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
88. Multiple myeloma
    Bhawna Sirohi, R Powles · 2004 · The Lancet
89. Teratogenic effects of thalidomide: molecular mechanisms
    Takumi Ito, Hideki Ando, Hiroshi Handa · 2011 · Cellular and Molecular Life Sciences
90. Thalidomide in the Treatment of Relapsed Multiple Myeloma
    S. Vincent Rajkumar, Rafaël Fonseca, Angela A. Dispenzieri, Martha Q. Lacy, John Anthony Lust, Thomas Elmer Witzig, Robert A. Kyle, Morie Abraham Gertz, Philip R. Greipp · 2000 · Mayo Clinic Proceedings
91. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, Patrizia Pregno, Norbert Pescosta, Vincenzo Callea, Clotilde Cangialosi, Tommaso Caravita, Fortunato Morabito, Pellegrino Musto et al. · 2006 · Blood
92. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
    Orhan Sezer, Christian Jakob, Jan Eucker, Kathrin Niemöller, Frauke Gatz, Klaus‐Dieter Wernecke, Kurt Possinger · 2001 · European Journal Of Haematology
93. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
    Michèle Cavo, Elena Zamagni, Patrizia Tosi, Claudia Cellini, Delia Cangini, Paola Tacchetti, Nicoletta Testoni, Michela Tonelli, Antonio De Vivo, Gualtiero Palareti et al. · 2004 · PubMed
94. Incidence and Risk Factors for Thalidomide Neuropathy: a Prospective Study of 135 Dermatologic Patients
    Sylvie Bastuji‐Garin, Sophie Ochonisky, P. Bouché, Romain Kroum Gherardi, Corinne Duguet, Zaya Djerradine, Florence Poli, Jean E. Revuz · 2002 · Journal of Investigative Dermatology
95. Endothelial cells in the bone marrow of patients with multiple myeloma
    A. Vacca · 2003 · Blood
96. Thalidomide and dexamethasone for resistant multiple myeloma
    Athanasios Anagnostopoulos, Donna Weber, Kim Rankin, Kay B. Delasalle, Raymond Alexanian · 2003 · British Journal of Haematology
97. Lenalidomide for the Treatment of B-Cell Malignancies
    Asher Alban Chanan-Khan, Bruce D. Cheson · 2008 · Journal of Clinical Oncology
98. E3 ligase ligand chemistries: from building blocks to protein degraders
    Izidor Sosič, Aleša Bricelj, Christian Steinebach · 2022 · Chemical Society Reviews
99. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
    Peter Leif Bergsagel, María‐Victoria Mateos, Norma Carmen Gutierrez, S. Vincent Rajkumar, Jesús F. San Miguel · 2012 · Blood
100. Potential pharmacological control of the NF-κB pathway
     Gautam Sethi, Vinay Tergaonkar · 2009 · Trends in Pharmacological Sciences